Achieve Life Sciences Inc (ACHV)
4.72
-0.03
(-0.63%)
USD |
NASDAQ |
May 08, 16:00
4.72
0.00 (0.00%)
After-Hours: 20:00
Achieve Life Sciences Enterprise Value: 163.86M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 163.86M |
May 06, 2024 | 157.70M |
May 03, 2024 | 163.35M |
May 02, 2024 | 161.81M |
May 01, 2024 | 155.98M |
April 30, 2024 | 151.53M |
April 29, 2024 | 157.70M |
April 26, 2024 | 159.07M |
April 25, 2024 | 157.87M |
April 24, 2024 | 156.67M |
April 23, 2024 | 155.30M |
April 22, 2024 | 152.22M |
April 19, 2024 | 155.64M |
April 18, 2024 | 157.70M |
April 17, 2024 | 157.70M |
April 16, 2024 | 151.19M |
April 15, 2024 | 153.59M |
April 12, 2024 | 149.99M |
April 11, 2024 | 151.53M |
April 10, 2024 | 151.19M |
April 09, 2024 | 150.50M |
April 08, 2024 | 150.50M |
April 05, 2024 | 153.93M |
April 04, 2024 | 154.61M |
April 03, 2024 | 158.38M |
Date | Value |
---|---|
April 02, 2024 | 154.61M |
April 01, 2024 | 158.04M |
March 28, 2024 | 156.84M |
March 27, 2024 | 155.98M |
March 26, 2024 | 160.78M |
March 25, 2024 | 161.12M |
March 22, 2024 | 158.72M |
March 21, 2024 | 158.72M |
March 20, 2024 | 160.78M |
March 19, 2024 | 157.35M |
March 18, 2024 | 158.72M |
March 15, 2024 | 158.38M |
March 14, 2024 | 153.93M |
March 13, 2024 | 152.56M |
March 12, 2024 | 150.16M |
March 11, 2024 | 150.16M |
March 08, 2024 | 151.53M |
March 07, 2024 | 151.19M |
March 06, 2024 | 152.90M |
March 05, 2024 | 151.53M |
March 04, 2024 | 152.56M |
March 01, 2024 | 94.72M |
February 29, 2024 | 86.89M |
February 28, 2024 | 95.57M |
February 27, 2024 | 96.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-9.453M
Minimum
Mar 16 2020
179.00M
Maximum
May 10 2023
45.80M
Average
35.89M
Median
Nov 26 2021
Enterprise Value Benchmarks
Accelerate Diagnostics Inc | 43.11M |
Atossa Therapeutics Inc | 125.81M |
ENDRA Life Sciences Inc | 0.6344M |
Perspective Therapeutics Inc | 1.072B |
Electromed Inc | 140.24M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -5.476M |
Total Expenses (Quarterly) | 4.386M |
EPS Diluted (Quarterly) | -0.24 |
Earnings Yield | -31.99% |
Normalized Earnings Yield | -30904.92 |